About

OrPro Therapeutics, Inc is a privately held preclinical-stage company pioneering a novel non-systemic biologic drug platform for treating severe respiratory and mucosal diseases, including cystic fibrosis, COVID-19 and beyond. The company’s differentiated approach targets both lung clearance and inflammation as well as obstructive/inflammatory disorders associated with non-respiratory mucosal surfaces in the body. Launched in 2013 with technology in-licensed from National Jewish Health, the company has secured Series A financing and significant non-dilutive grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation with over $5M raised to date. OrPro Therapeutics is a San Diego JLABS resident company (Johnson & Johnson Innovation). For more information visit www.orprotherapeutics.com.